Please complete all 4 questions below and click 'Submit'. You must answer a minimum of 3 questions correctly to earn a CE certificate.
a. Bone marrow biopsy and aspiration is required to confirm the diagnosis of AML
b. Accurate classification of AML necessitates the expertise of clinicians in myeloid malignancies
c. The patient’s history is a minor component of the diagnostic process
d. Genetic and cytogenetic abnormalities in AML can be predictive or prognostic
a. Rapid weight loss
b. Hypertension
c. Dyspnea
d. Sudden severe abdominal pain
a. CPX-351 is associated with prolonged cytopenias vs the 7+3 regimen
b. Cardiotoxicity rates are higher with the 7+3 regimen vs CPX-351
c. Grade ≥3 bacteremia is more frequent with CPX-351 vs the 7+3 regimen
d. The 7+3 regimen is associated with high rates of pneumonia vs CPX-351
a. Discontinue gilteritinib and switch to another FLT3 targeted agent
b. Interrupt and reduce gilteritinib dosage in patients with QTcF of >400 msec
c. Correct hypokalemia or hypomagnesemia prior to and during gilteritinib administration
d. Discontinue gilteritinib and switch to another appropriate class of agent for relapsed/refractory AML

 

 

Release Date: July 6, 2020
Expiration Date: July 6, 2021

Expected time to complete this activity as designed: 60 minutes
There are no fees for participating in or receiving credit for this online activity.

Program Overview

Staying abreast of the most up-to-date approaches for the care of patients with acute myeloid leukemia (AML) can be very challenging. This activity is designed to assist the nursing care team in remaining up-to-date with advances in AML, including a number of new therapies that have been approved in the past couple years.

Target Audience

This activity is designed for multidisciplinary healthcare providers in the community setting, including nurses and other allied healthcare professionals who provide care to patients with acute myeloid leukemia.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Discuss nursing considerations for patients with AML who are receiving frontline induction and post remission therapy
  • Provide best supportive care or palliative care measures for patients with relapsed/refractory AML to mitigate the toxic effects associated with current medications
  • Describe the current landscape of approved therapies for AML, including considerations for dosing, administration, side-effect monitoring, and management
  • Provide patient/family education on the risks and benefits of treatment options to facilitate shared decision making

Agenda

Acute Myeloid Leukemia: Incorporating the Latest Advances into Nursing Practice - Sandra E. Kurtin, PhD, ANP-C, AOCN

Instructions for Participation and Credit

This activity is eligible for credit through July 06, 2021. After this date, this activity will expire and no further credit will be awarded.

  1. Read the target audience, learning objectives, and faculty disclosures.
  2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
  3. Complete the educational content as designed.
  4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
  5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
  6. Certificates for CNE may be printed immediately after successfully completing the post-test and activity evaluation.

Faculty Biography

Sandra E. Kurtin, PhD, ANP-C, AOCN®
Assistant Professor of Clinical Medicine
Adjunct Clinical Assistant Professor of Nursing
The University of Arizona Cancer Center
Tucson, Arizona

Dr. Sandra Kurtin received her BSN, MS in oncology nursing, post-graduate certification in geriatric and adult practice, and most recently, her PhD in nursing at the University of Arizona. She is an Assistant Professor of Clinical Medicine and Adjunct Clinical Assistant Professor of Nursing at The University of Arizona College of Medicine and is a Hematology/Oncology Nurse Practitioner at The University of Arizona Cancer Center.

Dr. Kurtin is a founding board member and treasurer of the Advanced Practitioner Society for Hematology and Oncology (APSHO), as well as a board member of American Society of Hematology (ASH), American Society of Clinical Oncology (ASCO), American Academy of Nurse Practitioners (AANP), and Oncology Nursing Society (ONS). In addition, she is a member of the executive committee, board of directors and co-chair of the Nursing Leadership Board for the MDS Foundation. Dr. Kurtin is associate editor for The Journal of the Advanced Practitioner in Oncology and is an editorial board member for JCO Clinical Cancer Informatics, The Oncology Nurse, Oncology: Nurse Edition, and the ASCO People Living with Cancer website. She has presented numerous regional, national, and international lectures on oncology related topics and has published numerous articles in peer-reviewed journals including the New England Journal of Medicine, Cancer Nursing, Clinical Leukemia, Blood, Leukemia Research, The Journal of the Advanced Practitioner in Oncology, and The Clinical Journal of Oncology Nursing. Dr. Kurtin’s research focus is on heath technology engagement and communicative health literacy aimed at improving health self-management among older adult cancer survivors and their caregivers.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at cmettille@medicaled.com.

Provided by MediCom Worldwide, Inc.

This activity is supported by educational grants from Astex Pharmaceuticals, Celgene, a Bristol Myers Squibb Company, and Jazz Pharmaceuticals.



©2020 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242. No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.

Accreditation

MediCom NURSING CREDIT
Accreditation Statement: MediCom Worldwide, Inc., 101 Washington Street, Morrisville, PA 19067 is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.0 contact hour. Program Number: 20-025-123

Disclosure

As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty Disclosure

Dr. Sandra Kurtin has received honoraria related to formal advisory activities and as a consultant from Amgen Inc., AstraZeneca, Bristol-Myers Squibb Company, Celgene Corporation, Incyte Corporation, Jazz Pharmaceuticals plc, Novartis AG, Pharmacyclics, Inc., and Takeda Oncology.

Planning Committee Disclosures

The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Andrea Mathis, Project Manager, Wilma Guerra, Program Director, and Joan Meyer, RN, MHA, Executive Director, have no relevant financial relationships.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.